5 min read

Daily Filing Digest — Thursday, 8 Oct 2026

8 Oct 2026: TCS Q2 and the Porsche/MHP deal; Cochin Shipyard's ₹1,800 crore repair-yard JV; Evonile Pharma's ₹900 crore rights issue; more pledged Ajanta shares

TCS opened the Q2 results season: revenue up 11.2% to ₹73,188 crore, net profit up about 7.6%, and an operating margin of 24.0%, down from about 25.2% a year ago. It also agreed to buy MHP, Porsche's IT consulting arm. Cochin Shipyard asked shareholders to move its Kochi ship-repair yard into a 50:50 joint venture with Drydocks World at a ₹1,800 crore valuation. Evonile Pharma, the former Novartis India, plans a rights issue of up to ₹900 crore. And another 2.1% of Ajanta Pharma's shares were pledged as security for ₹3,873 crore of debentures issued by two other companies.

The ones to read first

Q2 FY26 Q2 FY27
Revenue ₹65,799 crore ₹73,188 crore (+11.2%)
Net profit, excluding one-offs ₹12,904 crore ₹13,884 crore (+7.6%, our arithmetic)
Operating margin ~25.2% (our arithmetic) 24.0%
  • In constant currency, growth was 2.8% year on year and 0.5% quarter on quarter; deals signed (TCV) were US$9.6 billion.
  • It says annualised AI revenue is US$3.1 billion, over 10% of revenue. Headcount: 598,056.
  • It agreed a five-year partnership with Porsche and will buy 100% of MHP, Porsche's German management and IT consulting subsidiary, subject to regulatory approvals. No price was disclosed.
  • Second interim dividend: ₹12 a share.

Full read: TCS Q2: 11% Growth in Rupees, 2.8% in Constant Currency. Where the Margin Went.

  • Cochin Shipyard asked shareholders to approve moving its International Ship Repair Facility at Willingdon Island, Kochi, into a 50:50 joint venture with Drydocks World (Dubai).
    • The yard goes in at a fair value of ₹1,800 crore: ₹900 crore in cash and ₹900 crore in JV shares.
    • The facility repairs commercial and naval vessels under 130 metres. E-voting runs from 9 October to 7 November.
  • Evonile Pharma (formerly Novartis India) approved a rights issue of partly paid shares for up to ₹9,000 million (₹900 crore). The price, ratio and record date are still to be set.
  • Ajanta Pharma: CTL Trusteeship disclosed a further 2.10% of Ajanta's shares pledged with it as security for debentures of up to ₹3,373 crore issued by Lenexis Foodworks and up to ₹500 crore by Inspira Realty 2.
    • Pledged shares rose to 7.41% of Ajanta's capital; all encumbrances, pledges included, are 13.53%.
    • The disclosure is dated 30 September.
  • Dr. Reddy's received a Form 483 with two observations after a USFDA pre-approval inspection of its FTO-11 plant at Pydibhimavaram, Andhra Pradesh (5–7 October).
  • Polycab India has appealed to the NCLAT against the 7 October insolvency admission over a disputed ₹2.79 crore. The hearing is listed for 9 October.

Rates: the repo hike, day two

  • UCO Bank raised its repo-linked lending rate to 8.30% from 8.05%, effective 8 October; its MCLR and base rate are unchanged. Its benchmark for the 10-year government bond yield rose to 7.32% from 7.09%.

Q2 updates

Deals and capital

Big holders

  • Clean Max Enviro: Augment India I Holdings sold 7.25% on the market on 28 September, leaving 2.25%.
  • Electrosteel Castings: Belgrave Investment Fund sold 4.68%, leaving 0.79%.
  • Swiggy: SBI Mutual Fund crossed 5%, to 5.13%.
  • Baba Arts: the promoter sold 62.29% off-market to Skybridge Interactive under a February share purchase agreement, a change of control.
  • Rolex Rings: ICICI Prudential Mutual Fund sold 10 lakh shares, cutting its stake to 5.23%.
  • Chalet Hotels and Shoppers Stop: the exchanges did not allow four Raheja entities to move from promoter group to public, because their majority owner, Mindspace REIT, is controlled by the same promoters (Shoppers Stop's filing).

Orders

Courts, tax and incidents

Ratings

People


Educational research, not investment advice. Every item above is drawn from the company's own filing on NSE or BSE, read from the primary document; derived figures are our arithmetic and are labelled. No buy/sell recommendations, no price targets, no share prices. Moat & Margin is not a SEBI-registered Research Analyst or Investment Adviser.